spacer
home > pmps > winter 2017 > thinking human
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Thinking Human

Two main challenges with human factors (HF) stand out at the moment: one is that it has become a ‘hot topic’ that people do not want to hear about anymore; the other is that it is perhaps not clear what the lasting and valuable contribution of it will be. However, it can have real benefits in the development of inhalers. It is important to look at the HF perspective and how it might contribute to future advancements in both medical devices and technology.

Innovative Inhalers


It is not helpful for HF to be possessive, or seek to claim ownership of any particular aspect of the development of inhalers or their life in the world. This perspective is just one voice among many, and countless progressions in inhalers occurred before HF were identified as an integral part of the design process. There are three aspects of the inhaler-user relationship where the industry looks to improve.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Julian Dixon is Director of HF at Team Consulting, the leading medical device development consultancy based in Cambridge, UK. He takes an active role in understanding emerging FDA expectations and practices with regard to HF, particularly as they apply to combination products. Predominantly in the respiratory and parenteral sectors, Julian has worked on a large number of drug delivery device development projects and has fulfilled a range of consultancy roles for clients including HF, facilitation, decision support and technical problem solving.
spacer
Julian Dixon
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Contemporary Issues in Comparator Trial Supply

Clinigen CTS

As trial design and execution becomes ever-more complex, initiatives to adapt, increase efficiency and control costs without compromising quality become paramount. Here, Clinigen CTS covers the broad issues and summarises the responses our industry is making in this increasingly demanding landscape.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement